85 related articles for article (PubMed ID: 15746476)
1. Use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection.
Kpozèhouen A; Alioum A; Anglaret X; Van de Perre P; Chêne G; Salamon R
Am J Epidemiol; 2005 Mar; 161(6):595-603. PubMed ID: 15746476
[TBL] [Abstract][Full Text] [Related]
2. Re: "use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection".
van Noord PA; van der Tweel I
Am J Epidemiol; 2005 Nov; 162(10):1033-5. PubMed ID: 16221807
[No Abstract] [Full Text] [Related]
3. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
4. A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trial.
Hiance A; Chevret S; Lévy V
J Clin Epidemiol; 2009 Apr; 62(4):431-437.e2. PubMed ID: 19010642
[TBL] [Abstract][Full Text] [Related]
5. Incidence of neutropenia in HIV-infected African adults receiving co-trimoxazole prophylaxis: a 6-year cohort study in Abidjan, Côte d'Ivoire.
Toure S; Gabillard D; Inwoley A; Seyler C; Gourvellec G; Anglaret X
Trans R Soc Trop Med Hyg; 2006 Aug; 100(8):785-90. PubMed ID: 16458337
[TBL] [Abstract][Full Text] [Related]
6. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
7. Quantifying and documenting prior beliefs in clinical trials.
Chaloner K; Rhame FS
Stat Med; 2001 Feb; 20(4):581-600. PubMed ID: 11223902
[TBL] [Abstract][Full Text] [Related]
8. Approaches for optimal sequential decision analysis in clinical trials.
Carlin BP; Kadane JB; Gelfand AE
Biometrics; 1998 Sep; 54(3):964-75. PubMed ID: 9750245
[TBL] [Abstract][Full Text] [Related]
9. Predictive checking for Bayesian interim analyses in clinical trials.
Daimon T
Contemp Clin Trials; 2008 Sep; 29(5):740-50. PubMed ID: 18571477
[TBL] [Abstract][Full Text] [Related]
10. Frequentist evaluation of group sequential clinical trial designs.
Emerson SS; Kittelson JM; Gillen DL
Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
[TBL] [Abstract][Full Text] [Related]
11. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
Zhao L; Woodworth G
Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
[TBL] [Abstract][Full Text] [Related]
12. Effect of early chemoprophylaxis with co-trimoxazole on nutritional status evolution in HIV-1-infected adults in Abidjan, Côte d'Ivoire.
Castetbon K; Anglaret X; Attia A; Toure S; Dakoury-Dogbo N; Messou E; N'Dri-Yoman T; Dabis F; Salamon R;
AIDS; 2001 May; 15(7):869-76. PubMed ID: 11399959
[TBL] [Abstract][Full Text] [Related]
13. Bayesian evaluation of group sequential clinical trial designs.
Emerson SS; Kittelson JM; Gillen DL
Stat Med; 2007 Mar; 26(7):1431-49. PubMed ID: 17066402
[TBL] [Abstract][Full Text] [Related]
14. Some design issues in trials of microbicides for the prevention of HIV infection.
Fleming TR; Richardson BA
J Infect Dis; 2004 Aug; 190(4):666-74. PubMed ID: 15272392
[TBL] [Abstract][Full Text] [Related]
15. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
Johnson VE; Cook JD
Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
[TBL] [Abstract][Full Text] [Related]
16. The effect of cotrimoxazole coadministrated with antituberculous drugs on serum transaminases in HIV-infected adults from the Ivory Coast.
Messou E; Anglaret X; Bonard D; Kouabena H; N'Dri-Yoman T; Dosso M; Dabis F;
Br J Clin Pharmacol; 2001 Nov; 52(5):611-2. PubMed ID: 11736872
[No Abstract] [Full Text] [Related]
17. Bayesian monitoring of clinical trials with failure-time endpoints.
Rosner GL
Biometrics; 2005 Mar; 61(1):239-45. PubMed ID: 15737099
[TBL] [Abstract][Full Text] [Related]
18. District-randomized phased implementation: strengthening the evidence base for cotrimoxazole for HIV-positive tuberculosis patients.
Godfrey-Faussett P
AIDS; 2003 May; 17(7):1079-81. PubMed ID: 12700460
[No Abstract] [Full Text] [Related]
19. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.
Grim SA; Rapp RP; Martin CA; Evans ME
Pharmacotherapy; 2005 Feb; 25(2):253-64. PubMed ID: 15767239
[TBL] [Abstract][Full Text] [Related]
20. Robust Bayesian approaches for clinical trial monitoring.
Carlin BP; Sargent DJ
Stat Med; 1996 Jun; 15(11):1093-106. PubMed ID: 8804141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
